CD274 and non-small cell lung carcinoma: A systematic analysis encompassing 16 clinical studies reported an overall irAE incidence of 22%, with severe irAEs (grade 3–4) affecting 4% of NSCLC patients under anti‐PD‐1/PD‐L1 treatment.9